Mr. Trenary has served as our President, Chief Executive Officer, and member of the Board since July 2021. He most recently was an Executive Advisor at InnFocus Inc., after serving as President & CEO for seven years, including the company’s acquisition in August 2016 by Santen Pharmaceutical Co., Ltd. InnFocus is an early-stage company, pending FDA approval of the PRESERFLO MicroShunt® glaucoma device, while pioneering other microsurgical solutions for glaucoma based on SIBS technology. Prior to that, he was President and CEO of G&H Orthodontics, a global medical device company, and served in a number of senior leadership positions at Advanced Medical Optics (AMO), Inc., including as President of the cataract business unit. Prior to that, Mr. Trenary held C-suite positions at Sunrise Technologies International, Inc., served as Senior Vice President, Worldwide Sales & Marketing / Officer at VidaMed, Inc. and held several senior leadership roles at Allergan, Inc., including as Senior Vice President and General Manager of the Medical Optics business unit. Over the course of his career, he has played a key role in seven acquisitions and closely led four major product launches in eye care medical devices.
Mr. Trenary received a B.S. in Business Administration from Miami University, Oxford, OH and his MBA from Michigan State University.
What is C Russell Trenary, III's net worth?
The estimated net worth of C Russell Trenary, III is at least $22,764.34 as of June 21st, 2022. Mr. Trenary, III owns 2,746 shares of Outlook Therapeutics stock worth more than $22,764 as of April 18th. This net worth evaluation does not reflect any other assets that Mr. Trenary, III may own. Learn More about C Russell Trenary, III's net worth.
How do I contact C Russell Trenary, III?
Has C Russell Trenary, III been buying or selling shares of Outlook Therapeutics?
C Russell Trenary, III has not been actively trading shares of Outlook Therapeutics in the last ninety days. Most recently, on Tuesday, June 21st, C Russell Trenary III bought 996 shares of Outlook Therapeutics stock. The stock was acquired at an average cost of $21.20 per share, with a total value of $21,115.20. Following the completion of the transaction, the chief executive officer now directly owns 2,746 shares of the company's stock, valued at $58,215.20. Learn More on C Russell Trenary, III's trading history.
Who are Outlook Therapeutics' active insiders?
Are insiders buying or selling shares of Outlook Therapeutics?
In the last year, Outlook Therapeutics insiders bought shares 1 times. They purchased a total of 1,882 shares worth more than $22,245.24. In the last year, insiders at the sold shares 1 times. They sold a total of 26,000 shares worth more than $592,800.00. The most recent insider tranaction occured on March, 28th when Director Yezan Munther Haddadin bought 1,882 shares worth more than $22,245.24. Insiders at Outlook Therapeutics own 5.3% of the company.
Learn More about insider trades at Outlook Therapeutics. Information on this page was last updated on 3/28/2024.
